MDGH Funded Population pharmacokinetic modelling for younger children

MDGH has established a population pharmacokinetic model for moxidectin and conducted population pharmacokinetic-pharmacodynamic analyses using data from healthy volunteers and onchocerciasis patients.  In this WP, an enhanced population pharmacokinetic (popPK) model will be developed to evaluate the impact of formulation alternatives and to better design future clinical studies in children, both to minimise burden of sampling and estimate an optimal dose of the paediatric formulation for one to three year old children.  Both the pharmacokinetic data generated in WP4 and a paediatric study (MDGH-MOX-1006, EDCTP project MoxiMultiDoseMod, RIA2017NCT-1843) will be utilised in this model.  This package is funded and led by MDGH.